Abstract

The cytokine erythropoietin (EPO) is a potent inducer of erythrocyte development and one of the most prescribed biopharmaceuticals. The action of EPO on erythroid progenitor cells is well established, but its direct action on hematopoietic stem and progenitor cells (HSPCs) is still debated. Here, using cellular barcoding, we traced the differentiation of hundreds of single murine HSPCs, after ex vivo EPO-exposure and transplantation, in five different hematopoietic cell lineages, and observed the transient occurrence of high-output Myeloid-Erythroid-megaKaryocyte (MEK)-biased and Myeloid-B-cell-Dendritic cell (MBDC)-biased clones. Single-cell RNA sequencing (ScRNAseq) analysis of ex vivo EPO-exposed HSPCs revealed that EPO induced the upregulation of erythroid associated genes in a subset of HSPCs, overlapping with multipotent progenitor (MPP) 1 and MPP2. Transplantation of Barcoded EPO-exposed-MPP2 confirmed their enrichment in Myeloid-Erythroid-biased clones. Collectively, our data show that EPO does act directly on MPP independent of the niche, and modulates fate by remodeling the clonal composition of the MPP pool.

Data availability

all data and scripts are available on the github of the Perie labhttps://github.com/PerieTeam/Eisele-et-al.-

The following data sets were generated

Article and author information

Author details

  1. Almut S Eisele

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Jason Cosgrove

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Aurelie Magniez

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Emilie Tubeuf

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Sabrina Tenreira Bento

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Cecile Conrad

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Fanny Cayrac

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Tamar Tak

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Anne-Marie Lyne

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Jos Urbanus

    Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  11. Leïla Perié

    CNRS UMR168, Physico-chimie, Institut Curie, Paris, France
    For correspondence
    leila.perie@curie.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0798-4498

Funding

Atip Avenir CNRS

  • Leïla Perié

Labex Celtisphybio (ANR-11-LABX-0038)

  • Leïla Perié

Idex Paris-Science-Lettres (ANR-10-IDEX-0001-02 PSL)

  • Leïla Perié

H2020 European Research Council (758170-Microbar)

  • Leïla Perié

H2020 Marie Skłodowska-Curie Actions (666003)

  • Almut S Eisele

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures were approved by the responsible national ethics committee (APAFIS#10955-201708171446318 v1).

Copyright

© 2022, Eisele et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,416
    views
  • 230
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Almut S Eisele
  2. Jason Cosgrove
  3. Aurelie Magniez
  4. Emilie Tubeuf
  5. Sabrina Tenreira Bento
  6. Cecile Conrad
  7. Fanny Cayrac
  8. Tamar Tak
  9. Anne-Marie Lyne
  10. Jos Urbanus
  11. Leïla Perié
(2022)
Erythropoietin directly remodels the clonal composition of murine hematopoietic multipotent progenitor cells
eLife 11:e66922.
https://doi.org/10.7554/eLife.66922

Share this article

https://doi.org/10.7554/eLife.66922

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Armando Montoya-Garcia, Idaira M Guerrero-Fonseca ... Michael Schnoor
    Research Article

    Arpin was discovered as an inhibitor of the Arp2/3 complex localized at the lamellipodial tip of fibroblasts, where it regulated migration steering. Recently, we showed that arpin stabilizes the epithelial barrier in an Arp2/3-dependent manner. However, the expression and functions of arpin in endothelial cells (EC) have not yet been described. Arpin mRNA and protein are expressed in EC and downregulated by pro-inflammatory cytokines. Arpin depletion in Human Umbilical Vein Endothelial Cells causes the formation of actomyosin stress fibers leading to increased permeability in an Arp2/3-independent manner. Instead, inhibitors of ROCK1 and ZIPK, kinases involved in the generation of stress fibers, normalize the loss-of-arpin effects on actin filaments and permeability. Arpin-deficient mice are viable but show a characteristic vascular phenotype in the lung including edema, microhemorrhage, and vascular congestion, increased F-actin levels, and vascular permeability. Our data show that, apart from being an Arp2/3 inhibitor, arpin is also a regulator of actomyosin contractility and endothelial barrier integrity.

    1. Immunology and Inflammation
    Alexandra a Aybar-Torres, Lennon A Saldarriaga ... Lei Jin
    Research Article

    The significance of STING1 gene in tissue inflammation and cancer immunotherapy has been increasingly recognized. Intriguingly, common human STING1 alleles R71H-G230A-R293Q (HAQ) and G230A-R293Q (AQ) are carried by ~60% of East Asians and ~40% of Africans, respectively. Here, we examine the modulatory effects of HAQ, AQ alleles on STING-associated vasculopathy with onset in infancy (SAVI), an autosomal dominant, fatal inflammatory disease caused by gain-of-function human STING1 mutations. CD4 T cellpenia is evident in SAVI patients and mouse models. Using Sting1 knock-in mice expressing common human STING1 alleles HAQ, AQ, and Q293, we found that HAQ, AQ, and Q293 splenocytes resist STING1-mediated cell death ex vivo, establishing a critical role of STING1 residue 293 in cell death. The HAQ/SAVI(N153S) and AQ/SAVI(N153S) mice did not have CD4 T cellpenia. The HAQ/SAVI(N153S), AQ/SAVI(N153S) mice have more (~10-fold, ~20-fold, respectively) T-regs than WT/SAVI(N153S) mice. Remarkably, while they have comparable TBK1, IRF3, and NFκB activation as the WT/SAVI, the AQ/SAVI mice have no tissue inflammation, regular body weight, and normal lifespan. We propose that STING1 activation promotes tissue inflammation by depleting T-regs cells in vivo. Billions of modern humans have the dominant HAQ, AQ alleles. STING1 research and STING1-targeting immunotherapy should consider STING1 heterogeneity in humans.